-
公开(公告)号：US20130252934A1
公开(公告)日：2013-09-26
申请号：US13782513
申请日：2013-03-01
Applicant: ARRAY BIOPHARMA INC. , GENENTECH, INC.
Inventor： James F. Blake , Mark Joseph Chicarelli , Rustam Ferdinand Garrey , John Gaudino , Jonas Grina , David A. Moreno , Peter J. Mohr , Li Ren , Jacob Schwarz , Huifen Chen , Kirk Robarge , Aihe Zhou
IPC: A61K31/506 , C07D401/04 , A61K45/06 , C07D413/14 , C07D409/14 , C07D417/14 , C07D405/14 , C07D401/14
CPC classification number: C07D401/04 , A61K31/444 , A61K31/506 , A61K31/513 , A61K31/53 , A61K45/06 , C07D401/14 , C07D403/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07F9/65586
Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
Abstract translation: 提供式I化合物或其立体异构体，互变异构体，前药或其药学上可接受的盐，其可用于治疗过度增生，疼痛和炎性疾病。 公开了使用式I化合物或其立体异构体，互变异构体，前药或其药学上可接受的盐在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。
-
公开(公告)号：US20240309020A1
公开(公告)日：2024-09-19
申请号：US18644056
申请日：2024-04-23
Applicant: Mirati Therapeutics, Inc. , Array BioPharma Inc.
Inventor： Xiaolun Wang , Aaron Craig Burns , James Gail Christensen , John Michael Ketcham , John David Lawson , Matthew Arnold Marx , Christopher Ronald Smith , Shelley Allen , James F. Blake , Mark Joseph Chicarelli , Joshua Ryan Dahlke , Donghua Dai , Jay Bradford Fell , John Peter Fischer , Macedonio J. Mejia , Brad Newhouse , Phong Nguyen , Jacob Matthew O'Leary , Spencer Pajk , Martha E. Rodriguez , Pavel Savechenkov , Tony P. Tang , Guy P.A. Vigers , Qian Zhao , Dean Russell Kahn , John Gaudino , Michael Christopher Hilton
IPC: C07D519/00
CPC classification number: C07D519/00
Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.
-
公开(公告)号：US11964989B2
公开(公告)日：2024-04-23
申请号：US17869575
申请日：2022-07-20
Applicant: Mirati Therapeutics, Inc. , Array BioPharma Inc.
Inventor： Xiaolun Wang , Aaron Craig Burns , James Gail Christensen , John Michael Ketcham , John David Lawson , Matthew Arnold Marx , Christopher Ronald Smith , Shelley Allen , James F. Blake , Mark Joseph Chicarelli , Joshua Ryan Dahlke , Donghua Dai , Jay Bradford Fell , John Peter Fischer , Macedonio J. Mejia , Brad Newhouse , Phong Nguyen , Jacob Matthew O'Leary , Spencer Pajk , Martha E. Rodriguez , Pavel Savechenkov , Tony P. Tang , Guy P.A. Vigers , Qian Zhao , Dean Russell Kahn , John Gaudino , Michael Christopher Hilton
IPC: C07D519/00
CPC classification number: C07D519/00
Abstract: Compounds that inhibit KRas G12D. In particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I):
or a pharmaceutically acceptable salt thereof.-
公开(公告)号：US11884664B2
公开(公告)日：2024-01-30
申请号：US17720070
申请日：2022-04-13
Applicant: Array BioPharma Inc.
Inventor： James Francis Blake , Mark Laurence Boys , Mark Joseph Chicarelli , Adam Wade Cook , Mohamed S. A. Elsayed , Jay Bradford Fell , John P. Fischer , Ronald Jay Hinklin , Yutong Jiang , Oren Teague McNulty , Macedonio J. Mejia , Martha E. Rodriguez , Christina Elizabeth Wong
IPC: C07D401/04 , A61K31/53 , C07D471/04 , A61P35/00 , C07D401/14 , C07D471/10 , C07D513/10 , A61K45/06
CPC classification number: C07D471/04 , A61P35/00 , C07D401/14 , C07D471/10 , C07D513/10 , A61K45/06
Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
-
公开(公告)号：US10689377B2
公开(公告)日：2020-06-23
申请号：US16191190
申请日：2018-11-14
Applicant: Mirati Therapeutics, Inc. , Array BioPharma Inc.
Inventor： James F. Blake , Laurence E. Burgess , Mark Joseph Chicarelli , James Gail Christensen , Adam Cook , Jay Bradford Fell , John P. Fischer , Matthew Arnold Marx , Macedonio J. Mejia , Pavel Savechenkov , Guy P. A. Vigers , Christopher Ronald Smith , Martha E. Rodriguez
IPC: C07D471/04 , A61P35/00 , C07D491/08
Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
-
Patent Agency Ranking
公开(公告)号：US20190144444A1
公开(公告)日：2019-05-16
申请号：US16191190
申请日：2018-11-14
Applicant: Mirati Therapeutics, Inc. , Array BioPharma Inc.
Inventor： James F. Blake , Laurence E. Burgess , Mark Joseph Chicarelli , James Gail Christensen , Adam Cook , Jay Bradford Fell , John P. Fischer , Matthew Arnold Marx , Macedonio J. Mejia , Pavel Savechenkov , Guy P.A. Vigers , Christopher Ronald Smith , Martha E. Rodriguez
IPC: C07D471/04 , C07D491/08 , A61P35/00
Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
-
公开(公告)号：US10125134B2
公开(公告)日：2018-11-13
申请号：US15814279
申请日：2017-11-15
Applicant: Mirati Therapeutics, Inc. , Array BioPharma Inc.
Inventor： James F. Blake , Laurence E. Burgess , Mark Joseph Chicarelli , James Gail Christensen , Jay Bradford Fell , John P. Fischer , John J. Gaudino , Erik James Hicken , Ronald Jay Hinklin , Matthew Randolf Lee , Matthew Arnold Marx , Macedonio J. Mejia , Martha E. Rodriguez , Pavel Savechenkov , Tony P. Tang , Guy P. A. Vigers , Henry J. Zecca
IPC: C07D471/04 , C07D519/00 , A61K31/519
Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
-
公开(公告)号：US09259470B2
公开(公告)日：2016-02-16
申请号：US14181418
申请日：2014-02-14
Applicant: Array BioPharma Inc. , Genentech, Inc.
Inventor： James F. Blake , Mark Joseph Chicarelli , Rustam Ferdinand Garrey , John Gaudino , Jonas Grina , David A. Moreno , Peter J. Mohr , Li Ren , Jacob Schwarz , Huifen Chen , Kirk Robarge , Aihe Zhou
IPC: A61K45/06 , C07D401/14 , C07D405/14 , C07D413/14 , C07D401/04 , C07D409/14 , C07D417/14 , C07D471/04 , A61K31/506 , C07F9/6558 , C07D403/04 , A61K31/513 , A61K31/53 , A61K31/444
CPC classification number: C07D401/04 , A61K31/444 , A61K31/506 , A61K31/513 , A61K31/53 , A61K45/06 , C07D401/14 , C07D403/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07F9/65586
Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
Abstract translation: 提供式I化合物或其立体异构体，互变异构体，前药或其药学上可接受的盐，其可用于治疗过度增生，疼痛和炎性疾病。 公开了使用式I化合物或其立体异构体，互变异构体，前药或其药学上可接受的盐在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。
-
公开(公告)号：US20230279025A1
公开(公告)日：2023-09-07
申请号：US18015691
申请日：2021-02-25
Applicant: Mirati Therapeutics, Inc. , Array BioPharma Inc.
Inventor： Xiaolun Wang , Aaron Craig Burns , James Gail Christensen , John Michael Ketcham , John David Lawson , Matthew Arnold Marx , Christopher Ronald Smith , Shelley Allen , James Francis Blake , Mark Joseph Chicarelli , Joshua Ryan Dahlke , Donghua Dai , Jay Bradford Fell , John Peter Fischer , Macedonio J. Mejia , Brad Newhouse , Phong Nguyen , Jacob Matthew O'Leary , Spencer Pajk , Martha E. Rodriguez , Pavel Savechenkov , Tony P. Tang , Guy P.A. Vigers , Qian Zhao , Dean Russell Kahn , John Gaudino , Michael Christopher Hilton
IPC: C07D519/00
CPC classification number: C07D519/00 , C07B2200/05
Abstract: The present invention relates to compounds that inhibit KRas G12D, In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.
-
公开(公告)号：US11453683B1
公开(公告)日：2022-09-27
申请号：US17005004
申请日：2020-08-27
Applicant: Mirati Therapeutics, Inc. , Array BioPharma Inc.
Inventor： Xiaolun Wang , Aaron Craig Burns , James Gail Christensen , John Michael Ketcham , John David Lawson , Matthew Arnold Marx , Christopher Ronald Smith , Shelley Allen , James F. Blake , Mark Joseph Chicarelli , Joshua Ryan Dahlke , Donghua Dai , Jay Bradford Fell , John Peter Fischer , Macedonio J. Mejia , Brad Newhouse , Phong Nguyen , Jacob Matthew O'Leary , Spencer Pajk , Martha E. Rodriguez , Pavel Savechenkov , Tony P. Tang , Guy P. A. Vigers , Qian Zhao , Dean Russell Kahn , John Gaudino , Michael Christopher Hilton
IPC: C07D519/00
Abstract: Compounds that inhibit KRas G12D; in particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.
-
-
-
-
-
-
-
-
-
Search Results
36
records
(took 0.21 seconds)
